e-learning
resources
Virtual 2020
Pre-Congress Content
Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Factors influencing best tolerated dose of pirfenidone (PFD) in patients with IPF
N. Agrawal (Mumbai, India), P. Vaidya (Mumbai, India), R. Shah (Mumbai, India), V. Chavhan (Mumbai, India), J. Leuppi (Liestal, Switzerland), A. Leuppi-Taegetmeyer (Liestal, Switzerland), P. Chhajed (Mumbai, India)
Source:
Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Session:
Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Session type:
E-poster session
Number:
1846
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. Agrawal (Mumbai, India), P. Vaidya (Mumbai, India), R. Shah (Mumbai, India), V. Chavhan (Mumbai, India), J. Leuppi (Liestal, Switzerland), A. Leuppi-Taegetmeyer (Liestal, Switzerland), P. Chhajed (Mumbai, India). Factors influencing best tolerated dose of pirfenidone (PFD) in patients with IPF. 1846
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Safety and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) receiving commonly used concomitant medications
Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease
Year: 2012
Best tolerated dose of Pirfenidone in patients with idiopathic pulmonary fibrosis
Source: International Congress 2019 – Interstitial lung disease registries
Year: 2019
The long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
Single therapeutic and supratherapeutic doses of indacaterol have little effect on systemic safety variables in patients with chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2007; 30: Suppl. 51, 357s
Year: 2007
Patterns of discontinuation in the long-term RECAP study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights
Year: 2017
Factors affecting compliance in OSA patients treated with APAP
Source: Annual Congress 2011 - Obstructive sleep apnoea: clinical aspects II
Year: 2011
Effects of low dose inhaled theophylline (ADC4022) co-administered with budesonide on inflammatory markers, lung function, and quality of life in COPD patients
Source: Annual Congress 2009 - New drugs for airways disease
Year: 2009
Single therapeutic and supratherapeutic doses of indacaterol have little effect on systemic safety variables in patients with asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 350s
Year: 2007
QVA149 once-daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: The ARISE study
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Factors influencing LAMA addition to COPD patients receiving ICS/LABA in clinical practice-RETRIEVE study.
Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies
Year: 2021
Efficacy of PO moxifloxacin in the treatment of AECOPD in patients with risk factors for poor outcomes
Source: Annual Congress 2009 - COPD case-finding and management in primary care
Year: 2009
Budesonide/formoterol for maintenance and relief
vs.
higher dose ICS/LABA therapy: outcomes in patients symptomatic on high-dose inhaled corticosteroids (HDICS)
Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment
Year: 2007
Concomitant medications and efficacy of nintedanib in patients with IPF
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
Effect of low dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): results from a real life study
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021
Efficacy and safety of etanercept in patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2006; 28: Suppl. 50, 767s
Year: 2006
Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials
Source: International Congress 2016 – IPF treatment I
Year: 2016
Dual bronchodilation with QVA149 and the free combination of indacaterol and glycopyrronium are equally safe and well tolerated in patients with COPD: The BEACON study
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Lung function effects and safety of fluticasone furoate (FF)/vilanterol (VI) in patients with COPD: Low-mid dose assessment
Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD
Year: 2012
The influence of high doses of N-acetylcysteine alone or in combination with inhaled corticosteroids on quality of life in patients with COPD
Source: Annual Congress 2011 - COPD management
Year: 2011
Efficacy and safety of combined use of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept